Clinical Trials Browser

Interventional × Carcinoma, Transitional Cell × Mitomycin × Clear all

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT07566156 2026-05-11

EV-309

Urogenital Diseases, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms, Female Urogenital Diseases, Male Urogenital Diseases

NCT06774131 2026-04-29

A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer

Phase 3 Recruiting

70 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT06331299 2026-01-15

UTOPIA

Phase 3 Active not recruiting

99 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT07189793 2025-09-24

OHAI-NMIBC-01

Phase 2 Not yet recruiting

106 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

NCT03658304 2024-11-05

Trial of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma

Phase 2 Completed

29 enrolled 11 charts

Genitourinary

Carcinoma, Transitional Cell

NCT05136898 2024-09-19

Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)

Phase 3 Completed

8 enrolled 18 charts

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06462001 2024-06-17

BCG + MMC: Adding Mitomycin C to BCG in High-risk, Non-muscle-invasive Bladder Cancer

Phase 3 Active not recruiting

500 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT04688931 2024-06-06

ATLAS

Phase 3 Terminated

282 enrolled 29 charts

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03558503 2022-09-16

OPTIMA II

Phase 2 Completed

63 enrolled 27 charts

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT01438112 2021-04-14

BOND

Phase 2/3 Terminated

22 enrolled

Genitourinary

Adenoviridae Infections, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Neoplasms, Virus Diseases

NCT02793128 2020-12-22

Olympus

Phase 3 Completed

71 enrolled 16 charts 1 FDA

Genitourinary

Carcinoma, Carcinoma, Transitional Cell

NCT04006691 2020-05-07

Retreatment

Phase 3 Withdrawn

Genitourinary

Carcinoma, Carcinoma, Transitional Cell

NCT02982395 2019-08-30

Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC

Phase 3 Terminated

36 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Carcinoma, Transitional Cell

NCT01200992 2017-08-24

EMBARC-RF

Phase 3 Terminated

84 enrolled 7 charts

Genitourinary

Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Mycobacterium Infections, Neoplasm Recurrence, Local, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms

Clinical Trials

ENVISION

EV-309

A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer

UTOPIA

OHAI-NMIBC-01

Trial of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma

Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)

BCG + MMC: Adding Mitomycin C to BCG in High-risk, Non-muscle-invasive Bladder Cancer

ATLAS

OPTIMA II

BOND

Olympus

Retreatment

Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC

EMBARC-RF